OpGen, Inc.

OPGN • Medical - Diagnostics & Research

Extraordinary move

OPGN+68.86%

vs. previous close $14.16

$23.91

▲ +9.75 (+68.86%)

Current price

EarningsLatest report: Dec 31, 2025

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$242.17M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Stable or improving margins · 78.2%Reasonable earnings multiple · 6.78Manageable debt level · 0.06Weak liquidity · 0.22Negative growth trend

Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$23.91

Change68.86%

Shares Out10.13M

Market Cap$242.17M

Enterprise Value$243.49M

Beta-1.93

P/E10.25

P/S8.02

P/B7.60

P/FCF-204.60

EV/Sales8.06

EV/EBITDA10.16

Price$23.91

Change68.86%

Shares Out10.13M

Market Cap$242.17M

Enterprise Value$243.49M

Beta-1.93

P/E10.25

P/S8.02

P/B7.60

P/FCF-204.60

EV/Sales8.06

EV/EBITDA10.16

EV/FCF-205.71

Earnings Yield9.75%

FCF Yield-0.49%

Dividend Yield0.00%

Gross Margin90.00%

Oper. Margin79.56%

Profit Margin78.21%

Debt/Eq0.06

Current Ratio0.22

Quick Ratio0.22

Target$0.67

Target Upside-97.20%

Target Median$0.67

Target Range0.67 - 0.67

Volume1.28K

Avg Volume5.58K

EPS Surprise2.23

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

90/100

Financial Strength

Debt, cash, stability

39/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

77/100

Why this score▼

Stable or improving margins · 78.2%Reasonable earnings multiple · 6.78Manageable debt level · 0.06Weak liquidity · 0.22Negative growth trend

Analyst view

Analyst sentiment and price target

OPGN

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Price Target

2026-06-15

Low

$0.67

Mean

$0.67

Median

$0.67

High

$0.67

Company Overview

IPO: 5/5/2015

Industry: Medical - Diagnostics & Research

P/B i: 7.60

Debt / Equity i: 0.06

Operating Margin: 79.56%

Net Margin: 78.21%

ROE i: -

ROIC: -

Financial Health

Score8 / 20

Debt / Equity: 0.06

Current Ratio: 0.22

Quick Ratio: 0.22

Status: Moderate

Warnings

Weak Liquidity
Weak quick ratio

🧾

No insider activity

No recent insider transactions available.

About the Company

OpGen, Inc.

OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U.S. and international markets. Its comprehensive product suite includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed to pinpoint various bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR) from bacterial colonies sourced from diverse specimen types. The company also offers Curetis CE-IVD-marked polymerase chain reaction (PCR)-based test kits for SARS-CoV-2 detection. Beyond diagnostics, OpGen provides sophisticated platforms like the ARES Technology Platform. This platform features the ARES reference database, which leverages next-generation sequencing technology and artificial intelligence-powered bioinformatics to predict antibiotic response for antimicrobial resistance. Another core offering is the Unyvero Platform, an automated, sample-to-answer molecular diagnostics system. It seamlessly integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and their associated antibiotic resistance markers. Fundamentally, OpGen harnesses molecular diagnostics and informatics to actively combat infectious diseases. The company empowers clinicians by providing crucial insights into life-threatening infections, thereby enhancing patient outcomes and significantly slowing the spread of infections caused by multidrug-resistant microorganisms. In a notable collaboration, OpGen is partnered with the New York State Department of Health and ILÚM Health Solutions, LLC, to establish a research program. This initiative focuses on the detection, tracking, and effective management of antimicrobial-resistant infections within healthcare institutions. Established in 2001, OpGen, Inc. maintains its corporate headquarters in Rockville, Maryland.

Source - link

Peers

ANPCF BLMH CNFHF INTI LIANY NGMDF NSVGF PMSNF PNPL UNVC

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

📰

No news available now

Check back later.

Earnings Surprises

Period	Estimate	Actual	Surprise
2025-08-21	-1.4	0.833	2.233
2024-11-15	-1.6	1.35	2.95
2024-08-19	-1.7	-1.18	0.52
2024-07-08	-1.9	0.21	2.11
2024-06-03	-0.9	-2.52	-1.62
2023-11-14	-4.3	-4.6	-0.3
2023-08-10	-7.1	-9.3	-2.2
2023-05-15	-1.2	-12.5	-11.3
2023-03-29	-2	-19	-17
2022-11-10	-2.4	-30	-27.6
2022-08-11	-30	-26	4
2022-05-12	-32	-30	2